Advanced search
Publication Cover
Redox Report
Communications in Free Radical Research
Volume 9, 2004 - Issue 4
Submit an article Journal homepage
475
Views
56
CrossRef citations to date
0
Altmetric
Reviews

Bioactive carotenoids: potent antioxidants and regulators of gene expression

Laura M. HixDepartment of Cell and Molecular Biology and Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii, USA
,
Samuel F. LockwoodHawaii Biotech, Inc., Aiea, Hawaii, USA
&
John S. BertramCancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii, USA
Pages 181-191 | Published online: 19 Jul 2013

  • Beecher GR, Khachik F. Qualitative relationship of dietary and plasma carotenoids in human beings. Ann NY Acad Sci 1992; 669: 320–321.
  • Britton G. Structure and properties of carotenoids in relation to function. FASEB J1995; 9: 1551-1558.
  • Means AL, Gudas U. The roles of retinoids in vertebrate development. Annu Rev Biochem 1995; 64: 201–233.
  • Frank HA, Cogdell RJ. Carotenoids in photosynthesis. Photochem Photobiol 1996; 63: 257–264.
  • Bramley PM. Carotenoid biosynthesis: a target site for bleaching herbicides. Biochem Soc Trans 1994; 22: 625–629.
  • Bernstein PS, Khachik F, Carvalho LS et al. Identification and uantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res 2001; 72: 215–223.
  • Bernstein PS, Zhao DY, Wintch SW et al. Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Ophthalmology 2002; 109: 1780–1787.
  • Matthews-Roth MM. Recent progress in the medical applications of carotenoids. Pure Appl Chem 1991; 63: 147–156.
  • Burton GW, Ingold KU. I3-Carotene: an unusual type of lipid antioxidant. Science 1984; 224: 569–573.
  • Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–1155.
  • Albanes D, Heinonen OP, Taylor PR et al. a-Tocopherol andl3-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560–1570.
  • Martin HD, Jager C, Ruck C et al. Anti- and prooxidant properties of carotenoids. J Prakt Chem 2004; 341: 302–308.
  • Victor VM, Rocha M, De La FM. Immune cells: free radicals and antioxidants in sepsis. Int Immunopharmacol 2004; 4: 327–347.
  • Baran CP, Zeigler MM, Tridandapani S, Marsh CB. The role of ROS and RNS in regulating life and death of blood monocytes. Curr Pharm Des 2004; 10: 855–866.
  • Marnett U. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361–370.
  • Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 1993; 101 (Suppl. 5): 35-44.
  • Kuipers EJ, Meuwissen SG. Helicobacter pylori and gastric carcinogenesis. Scand J Gastroenterol Suppl 1996; 218: 103–105.
  • Nishino H, Jinno K. Prevention of hepatitis C virus-induced liver cancer by natural carotenoids and vitamin E. Proceedings of Frontiers in Cancer Prevention Research, AACR Conference 2002; 107,202.
  • Watanabe S, Kitade Y, Masaki T et al. Effects of lycopene and Sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr Cancer 2001; 39: 96–101.
  • Lee SJ, Bai SK, Lee KS et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells 2003; 16: 97–105.
  • von Baeyer H, Hopfenmuller W, Riedel E, Affeld K. Atherosclerosis: current concepts of pathophysiology and pharmacological intervention based on trial outcomes. Clin Nephrol 2003; 60 (Suppl 1): S31-S48.
  • Iwamoto T, Hosada K, Hirano R et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 2000; 7:216–222.
  • Clarke R, Armitage J. Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. Cardiovasc Drugs Ther 2002; 16: 411–415.
  • Rissanen TH, Voulilanen S, Nyyssonen K et al. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2001; 85: 749–754.
  • Dwyer JH, Navab M, Dwyer KM et al. Oxygenated carotenoid lutein and progression of early atherosclerosis - The Los Angeles Atherosclerosis Study. Circulation 2001; 103: 2922–2927.
  • Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 1997; 58: 95–117.
  • Cobbold CA, Sherratt JA, Maxwell SR. Lipoprotein oxidation and its significance for atherosclerosis: a mathematical approach. Bull Math Biol 2002; 64: 65–95.
  • Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann NY Acad Sci 1989; 570; 7–22.
  • Cooney RV, Kappock TJ, Pung A, Bertram JS. Solubilization, cellular uptake, and activity of 13-carotene and other carotenoids as inhibitors of neoplastic transformation in cultured cells. Methods Enzymol 1993; 214: 55–68.
  • Zsila F, Simonyi M, Lockwood SF. Interaction of the disodium disuccinate derivative of meso-astaxanthin with human serum albumin: from chiral complexation to self-assembly. Bioorg Med Chem Lett 2003; 13: 4093–4100.
  • Gross GJ, Lockwood SF. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative. Life Sci 2004; 75: 215–224.
  • Cardounel AJ, Dumitrescu C, Zweier JL, Lockwood SF. Direct superoxide anion scavenging by a disodium disuccinate astaxanthin derivative: relative efficacy of individual stereoisomers versus the statistical mixture of stereoisomers by electron paramagnetic resonance imaging. Biochem Biophys Res Commun 2003; 307: 704–712.
  • Showalter LA, Weinman SA, Osterlie M, Lockwood SF. Plasma appearance and tissue accumulation of non-esterified, free astaxanthin in C57B1/6 mice after oral dosing of a disodium disuccinate diester of astaxanthin (Heptax). Comp Biochem Physiol [C] Toxicol Pharmacol 2004; 137: 227–236.
  • Hix LM, Lockwood SF, Bertram JS. Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives. Cancer Lett 2004; 211: 25–37.
  • Yeager M. Structure of cardiac gap junction intercellular channels. J Struct Biol 1998; 121: 231–245.
  • Kang KS, Yun JW, Yoon BS et al. Preventive effect of epicatechin and ginsenoside Rb2 on the inhibition of gap junctional intercellular communication by TPA and H202. Cancer Lett 2000; 152: 97–106.
  • Mayne ST. Beta-carotene, carotenoids, and disease prevention in humans. FASEB J 1996; 10:690–701.
  • Reznikoff CA, Bertram JS, Brankow DW, Heidelberger C. Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division. Cancer Res 1973; 33: 2339–2349.
  • Merriman R, Bertram JS. Reversible inhibition by retinoids of 3-methylcholanthrene-induced neoplastic transformation in C3H10T1/2 cells. Cancer Res 1979; 39: 1661–1666.
  • Pung A, Rundhaug JE, Yoshizawa CN, Bertram JS. 13-Carotene and canthaxanthin inhibit chemically- and physically-induced neoplastic transformation in 1 OT1/2 cells. Carcinogenesis 1988; 9: 1533–1539.
  • Bertram JS, Pung A, Churley M et al. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 1991; 12: 671–678.
  • Neveu M, Bertram JS. Gap junctions and neoplasia. Adv Mol Cell Biol 2000; 30: 221–262.
  • Loewenstein WR. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 1979; 560: 1–65.
  • Nicholson BJ, Weber PA, Cao F et al. The molecular basis of selective permeability of connexins is complex and includes both size and charge. Braz J Med Biol Res 2000; 33: 369–378.
  • Mehta PP, Bertram JS, Loewenstein WR. Growth inhibition of transformed cells correlates with their junctional communication with normal cells. Cell 1986; 44: 187–196.
  • Hossain MZ, Wilkens LR, Mehta PP, Loewenstein WR, Bertram JS. Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. Carcinogenesis 1989; 10: 1743–1748.
  • Matesic DF, Rupp HL, Bonney WJ, Ruch RJ, Trosko JE. Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells. Mol Carcinogenesis 1994; 10: 226–236.
  • King TJ, Fukushima L, Bertram JS. Connexins and carcinogenesis: upregulated expression of connexin 43 by cancer preventive agents or by gene transfer decreases proliferation and expression of neoplasia. In: Werner R (ed) Gap Junctions. Amsterdam: IOS Press, 1998; 357–361.
  • Beyer EC, Paul DL, Goodenough DA. Connexin family of gap junction proteins. J Membr Biol 1990; 116: 187–194.
  • Sohl G, Willecke K. An update on connexin genes and their nomenclature in mouse and man. Cell Commun Adhes 2003; 10: 173–180.
  • Zhang L-X, Cooney RV, Bertram JS. Carotenoids up-regulate connexin 43 gene expression independent of their pro-vitamin A or antioxidant properties. Cancer Res 1992; 52: 5707–5712.
  • Zhang L-X, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. Carcinogenesis 1991; 12: 2109–2114.
  • King TJ, Fukushima LH, Hieber AD et al. Reduced levels of connexin 43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 2000; 21: 1097–1109.
  • King TJ, Fukushima LH, Yasui Y, Lampe PD, Bertram JS. Inducible expression of the gap junction protein connexin 43 decreases the neoplastic potential of HT-1080 human fibrosarcoma cells in vitro and in vivo. Mol Carcinog 2002; 35: 29–41.
  • Sutherland BM, Bennett PV. Transformation of human cells by DNA transfection. Cancer Res 1984; 44: 2769–2772.
  • Meyskens FL, Surwit E, Moon Jr TE et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans- retinoic acid: A randomized trial. J Natl Cancer Inst 1994; 86: 539–543.
  • Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795–801.
  • Garewal H, Meyskens Jr F, Katz RV. I3-carotene produces sustained remissions in oral leukoplakia: results of a 1 year randomized, controlled trial. Proc Am Soc Clin Oncol 1995; 14:496.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.